What changed for peptides and the FDA in 2026?

On October 30, 2026, the Department of Health and Human Services opened a regulated path to six peptides that had been off limits since 2023: BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax. Licensed US pharmacies can now compound them by prescription under ten quality and reporting rules. This is permission to compound, not FDA approval.

We have been following this space closely at Superpower, and we are offering early access to the admitted compounds by prescription, after a licensed clinician reviews your health history and decides whether one fits you. The science is young and the rules are still moving, so we will keep following both and update this library as they change. This brief explains what has changed as of November 2, 2026, what did not, and where we stand. It explains a change in federal enforcement policy; it is not legal advice, and nothing in it means that any peptide has been approved or found safe by FDA.

What does the change mean, in plain language?

What are peptides?

Peptides are short chains of amino acids, the building blocks of proteins. Your body makes thousands of them, and uses them as messengers: insulin tells cells to take up sugar, oxytocin shapes labor and bonding, GLP-1 signals fullness after a meal. Because they are the body's own signalling language, peptides have long interested medicine. Some have become fully approved drugs after decades of trials, from insulin a century ago to the GLP-1 medicines of today.

These six peptides are different. They are synthetic copies or fragments of signalling molecules, studied mostly in animals and cells, with little or no controlled research in people. They are not approved medicines in the way we usually think about medicine: no regulator has reviewed trials and concluded that they work, or established how safe they are. That is the starting point for everything that follows.

Why were these six peptides off limits until 2026?

For three years, these six peptides were off the table in the US. If you follow fitness, recovery, or longevity circles, you may well have heard of people using them anyway. Almost all of that supply came from unregulated "research use only" sellers, where laboratory testing has repeatedly found underdosed, contaminated, or mislabeled vials. The restriction came from the FDA: in September 2023, it told pharmacies not to compound BPC-157, TB-500, KPV, MOTS-c, Epitalon, or Semax, citing possible immune reactions, impurities, and very little human data.

Where do these six peptides stand today?

The thinking in Washington shifted over the following years, and the argument that won was about safety of supply: if people were going to use these peptides anyway, a tested, traceable, prescription-only source beat the gray market.

On October 30, 2026, the Department of Health and Human Services acted on that logic and set the terms: provided that a licensed pharmacy or physician meets ten requirements, they are allowed to compound the six peptides for a patient who holds a prescription. The requirements cover ingredients from FDA-registered manufacturers, a certificate of analysis for every lot, a patient-specific prescription, clear labeling, approved routes only, and reporting of any serious side effects. Done right, this puts peptides on a path where the evidence can be built properly, in the open, and opens the way to what has been missing for decades: systematic safety reporting, controlled human studies, and answers members can actually trust.

What hasn't changed?

What has remained unchanged is equally important: none of the six are FDA-approved.

That phrase deserves context: FDA does not approve dietary supplements¹ for safety and effectiveness before they are sold either, so nearly everything on a supplement shelf is also not FDA-approved. The difference with these peptides is that they are prescription medicines, made for you by a licensed pharmacy under the ten conditions, with a clinician in the loop. The FDA has not reviewed them the way it reviews a new medicine, and its own scientists were not convinced² in July 2026; the advisory committee voted narrowly in favor anyway³. In other words, the door opened because regulators decided a safer, supervised supply was better than the alternative, not because new evidence arrived.

HHS has also said it can revisit the policy if safety problems appear. Our scientists will closely monitor the space and the recommendations as they are set out, and we will update you as things change.

What does this mean for you?

For you, this means four things.

1. 1.You can get these peptides only with a prescription from a licensed clinician, who decides whether one is appropriate for you.
2. 2.What you receive is a compounded medicine made to order, not a manufactured product FDA has reviewed.
3. 3.The rules may change again. The HHS policy is interim and FDA's formal rulemaking is still ahead⁴; either could widen, narrow, or end access, which is why this brief carries a date and we revise it when something moves.
4. 4.Superpower will act in good faith on the information available to us. Everything we tell you will be grounded in the published science and in current government guidance, and when either changes, so will we.

What is the timeline of changes?

1. 1.September 2023: FDA says no. FDA keeps a list of raw ingredients that pharmacies may and may not use to make custom medicines. In September 2023 it puts more than a dozen peptides, including these six, on the "do not use" side of that list, citing possible immune reactions, impurities, and very little human data. Licensed pharmacies stop making them, and the unregulated market fills the gap.
2. 2.April 2026: FDA reopens the question. FDA announces a July advisory-committee meeting⁵ on seven peptides and takes them off the "do not use" side of the list while it looks again. HHS Secretary Robert F. Kennedy Jr. had publicly argued that keeping the peptides off the list pushed people toward unregulated products.
3. 3.July 23 to 24, 2026: the committee votes yes, narrowly. FDA's own scientific reviewers find the evidence on quality, effectiveness, and safety insufficient⁶ for all seven peptides. The committee still votes to recommend six of them, giving weight to patient access to a tested, traceable supply. It rejects the seventh, emideltide (also known as DSIP, a "delta sleep-inducing" peptide proposed for insomnia, narcolepsy, and opioid withdrawal), by 6 votes to 7⁷: FDA's reviewers had found no safety data⁸ for the injected form and no effectiveness studies for that route, and the members voting no cited the poor quality of the evidence⁹.
4. 4.October 30, 2026: HHS allows compounding, with conditions. The Secretary of Health and Human Services publishes an interim policy: the government will not take action against licensed pharmacies¹⁰ and physicians that compound the six peptides, provided they meet ten conditions on sourcing, testing, labeling, routes, and reporting. The policy states plainly that this is not FDA approval.

Why did the rules change?

The case for change was about supply, not new evidence. Supporters argued that people were already using these peptides from unregulated sources, and that a prescription-only, tested, traceable supply is safer than the alternative. Critics, including FDA's reviewers¹¹ and consumer-safety groups¹², argued that access should follow evidence rather than precede it¹³. Both are right about the facts: the supply is now safer; the evidence is unchanged.

Where does Superpower stand?

At our core we are an evidence-based company, and the evidence has not changed. We read October 30 for what it is: a change in access, not a change in what is known. We have our own views, and a team of clinicians and scientists who follow clinical evidence closely, often ahead of official guidance. We were convinced early that inflammation drives much of heart disease, and built markers of inflammation into our cardiovascular panels well before mainstream guidelines caught up.

• We tell you the tier of evidence behind every claim, and we write only as strongly as the evidence allows. For most of these peptides, that means animal and laboratory data rather than human trials.
• We say "not FDA-approved" plainly, never as a footnote.
• Our clinicians prescribe only when a peptide is appropriate for you, and they may decline.
• We source only under the policy's ten conditions: FDA-registered manufacturers, a certificate of analysis for every lot, and US-licensed pharmacies.
• We report problems. Serious side effects are reported to FDA's MedWatch program and to your state, and we show you how to report them yourself.
• We update this library whenever the rules or the evidence change.

What is compounding, and why does it matter for peptides?

"Compounding" is when a licensed pharmacist or physician prepares a medicine for one specific patient, outside FDA's approval process. It is how a pharmacy makes a liquid version of a pill for a child, or leaves out a dye someone is allergic to. It is a normal, long-standing part of pharmacy. Because compounded medicines skip FDA's review, though, the rules around who may compound what matter a great deal, and Congress rewrote them in 2013¹⁴ in the Drug Quality and Security Act after quality failures at one large compounder showed what oversight needs to cover. Those rules are the ones that govern the six peptides today.

What is the difference between 503A and 503B?

That law created two tracks:

• Section 503A is the traditional one: a state-licensed pharmacy, a federal facility, or a licensed physician compounds for a named patient with a prescription. These products do not go through FDA approval, do not carry standard FDA labeling, and are not made under the manufacturing rules (CGMP) that approved drugs follow; state pharmacy boards are the main overseers.
• Section 503B covers "outsourcing facilities": larger operations that register with FDA, are inspected by FDA, follow CGMP, and can compound in bulk without patient-specific prescriptions.

The October 30 policy covers 503A only¹⁵.

Why is the 503A bulks list the only door for these peptides?

Here is the catch for peptides. Under 503A, a pharmacy may use a raw ingredient only if one of three things is true¹⁶:

1. 1.it has an official quality standard (a USP or NF monograph);
2. 2.it is an ingredient of an FDA-approved drug; or
3. 3.it is on FDA's "503A bulks list"¹⁷.

None of the six peptides passes any of those tests, so the bulks list is the only door. Getting on the list is slow. FDA and its Pharmacy Compounding Advisory Committee (PCAC)¹⁸ weigh four things¹⁹:

1. 1.whether the substance is well characterized chemically;
2. 2.whether it has historically been compounded;
3. 3.whether there is evidence it works; and
4. 4.whether it raises safety concerns.

The committee votes, and then FDA has to write a rule²⁰, take public comments, and finalize it, with no deadline. The one cycle completed so far ran from December 2016 to February 2019.

While the list was being built, FDA sorted nominated substances into interim categories. Category 1 meant "possibly eligible, and we will not act against compounders in the meantime". Category 2 meant "we see significant safety risks, and we may act". Category 3 meant "not enough information". The six peptides were put in Category 2, which in practice meant pharmacies could not make them.

Why did FDA restrict these peptides in 2023?

In September 2023, FDA put BPC-157 and more than a dozen other peptides²¹ on the "do not use" side of its list. Its reasons were the ones you would expect from a cautious regulator looking at thin data: injected peptides can trigger immune reactions²², products made without tight manufacturing controls can carry impurities, and almost none of these substances had been tested properly in people.

Because none of the six had ever been on the "allowed for now" side, there was nothing to fall back on. From that point, a licensed pharmacy could not make them.

Not everyone accepted the decision. Compounding companies sued FDA²³ over how it had handled four other peptides²⁴, arguing that the agency had not explained its reasoning; the Alliance for Pharmacy Compounding put the complaint simply: "'Trust us' is not a sufficient explanation for agency actions." That lawsuit did not involve the six peptides covered here, but it set the tone. By 2024 the argument was no longer only about the science; it was also about how the decisions were being made.

What changed between 2024 and 2026?

The change began outside the lab. As Secretary of Health and Human Services, Robert F. Kennedy Jr. argued that keeping peptides out of licensed pharmacies did not stop people using them; it only pushed them toward sellers nobody checked. Speaking on The Joe Rogan Experience²⁵ in February 2026, he said he was "a big fan of peptides²⁶," had used them himself, and that "with the gray market you have no idea if you're getting a good product²⁷." At least one member of Congress, Rep. Diana Harshbarger, wrote to him in 2025 asking for the limits to be lifted²⁸, and peptides became a signature issue for the "Make America Healthy Again" movement. The argument HHS kept making was simple: the demand is real, it is being met by unregulated imports, and it would be safer inside licensed pharmacies.

In April 2026, FDA scheduled a public meeting of its advisory committee²⁹ for July 23 and 24 to review seven peptides, including the six discussed here. At the same time it took them off its "do not use" list, because the original requests to add them had been withdrawn³⁰. That was a procedural step rather than a permission: until the committee had met and HHS had acted, pharmacies still could not compound them.

What did FDA's scientists find in July 2026, and how did the committee vote?

What did FDA's scientific reviewers find?

The most useful part of the July meeting, for a member, is what FDA's scientific reviewers found when they examined the seven peptides. Four things stood out, and they are the same four questions we ask of every peptide in this library.

• Is it well characterized? For none of the seven could FDA say with confidence exactly what the substance is in the form being sold: the purity, impurity, and breakdown data needed to set quality standards were missing⁶. One reviewer put it bluntly about BPC-157³¹: FDA still could not say precisely what it is³².
• Has it been used in compounding before? Little or unclear history for all seven.
• Is there evidence it works? For every use evaluated, the human evidence was too thin³³ to say. Most of what exists is animal and cell research, which often does not carry over to people.
• Is it safe? Not established for any of them³⁴. Injected peptides can provoke immune reactions, and because compounding pharmacies are not generally required to report side effects to FDA, there is no system that would have caught problems so far.

On those grounds the reviewers recommended against adding any of the seven³⁵.

How did the advisory committee vote?

The committee weighed the same findings against a different question: given that people were already using these peptides from unregulated sources, would a tested, prescription-only supply do more good than harm? By narrow margins³⁶, it answered yes for six of the seven³⁷. Those voting yes pointed to patients already injecting product of unknown purity; those voting no pointed to the lack of controlled trials and the absence of any system for tracking side effects. Both concerns are real, and both shape how we approach these peptides.

What does the October 2026 HHS peptide policy say?

The policy came from the Office of the Secretary³⁸ of HHS. Its stated aims are to discourage the use of research-use-only peptides³⁹ from foreign manufacturers, to offer "a more controlled alternative," and to advance "patient choice and freedom while appropriately protecting patient safety."

What are the ten conditions?

HHS will not act against a state-licensed pharmacy, federal facility, or licensed physician as long as all ten hold:

1. 1.The peptide is one of the six.
2. 2.Its identity and route of administration match the policy's appendix⁴⁰.
3. 3.The raw ingredient comes from an FDA-registered facility with a certificate of analysis that meets FDA's testing criteria, including tests for endotoxin and microbial contamination in injectables.
4. 4.The original manufacturer, not a repacker or distributor, is registered, follows CGMP, and is named on the certificate.
5. 5.The compounder reports what it made, every serious side effect, and any quality problem to FDA's MedWatch program and to the state, and tells patients how to report.
6. 6.The label reads "This is a compounded drug product. Not for resale."
7. 7.One peptide per product; no blends.
8. 8.Oral products come with evidence that the specific formulation is absorbed in humans.
9. 9.The only device packaged with it is an FDA-cleared syringe.
10. 10.Everything else in federal drug law still applies, including the patient-specific prescription.

Which routes does the policy permit for each peptide?

The policy also fixes how each peptide may be given:

• BPC-157: injection under the skin or into muscle, by mouth, or applied to the skin
• TB-500: injection under the skin or into muscle
• MOTS-c: injection under the skin or into muscle
• Epitalon: injection under the skin or into muscle, in intermittent courses
• Semax: nasal spray or drops
• KPV: applied to the skin, or by mouth

What is the policy not?

The policy says in its own words that compounded drugs "are not FDA-approved" and that "FDA does not review their safety, effectiveness, or quality before they are marketed." It adds nothing to the bulks list and covers only 503A compounding, and the Federal Register notice states that it "does not establish any rights for any person and is not binding on HHS or the public⁴¹." It lasts until each peptide is dealt with in a final rule⁴², and HHS can revisit it if a safety signal or product-quality problem appears. Public comments were due two weeks after publication (November 13, 2026).

About this article. The facts, dates, vote counts, and quotations above were checked against the HHS policy and its appendices, the Federal Register notices, FDA's July 2026 meeting materials, and the reporting listed here. Rules in this area are still moving; we review this page when the policy, the bulks list, or FDA guidance changes.

More peptide science